Sangamo Therapeutics is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies.

Research Grants 24 show all


$104K
2004

$100K
2006

$5.7M
2009

$1.6M
2015

$2.1M
2017

Publications 151 show all

  • 21
    Zinc Fingers
  • 10
    Gene Expression Regulation
  • 10
    Zinc Fingers/genetics
  • 9
    Transcription Factors/genetics
  • 8
    Gene Targeting/methods
  • 8
    Genetic Therapy/methods
  • 8
    Transcription Factors/metabolism
  • 7
    Genome
  • 6
    Chromatin/genetics
  • 5
    Chromatin/metabolism

Patents 1,406show all

  • 589
    C12N - Microorganisms or enzymes
  • 460
    C07K - Peptides
  • 291
    A61K - Preparations for medical, dental, or toilet purposes
  • 125
    C12Y - Enzymes
  • 123
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 80
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 64
    A01K - Animal husbandry
  • 47
    G16B - Bioinformatics, i.e. information and communication technology [ict] specially adapted for genetic or protein-related data processing in computational molecular biology
  • 23
    C12P - Fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture
  • 13
    C40B - Combinatorial chemistry

Clinical Trials 24show all

11Phase 1/Phase 27Phase 16Phase 2

SEC Filings show all


172
8-K

61
10-Q

19
10-K

1
S-1

Contact Information

Point Richmond Tech Center II 501 Canal Blvd
Richmond, CA 94804
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$93,200,000251-5002018-04-27Ipo

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2018-04-27$8,000,000GrantCalifornia Institute for Regenerative Medicine
2018-02-07$11,000,000GrantNational Institutes of Health
2013-09-24$74,200,000Post Ipo Equity